We contribute to society through state-of-the art non-clinical pharmacological research using our patented "STAM™ mice" technology
In order to develop new drugs, it is important to be able to accurately measure the effectiveness of drug candidates at a nonclinical trial stage.
Our "STAM™ mice" are disease model mice that more accurately reflect human pathology and therefore play a major role in pharmacology studies.
SERVICE
We support more than 600 pharmaceutical companies and bio-ventures in over 29 countries with our cutting-edge research and pharmacology studies.
SERVICE
Thanks to our extensive experience in various treatment fields, we are able to provide quick and decisive support for our client's pharmacological studies.
SERVICE
Our expert pathologists support the construction of experimental analysis systems, data acquisition and explanation of results, and maximize the information from the histology samples of pharmacology studies conducted by clients.
TRIAL
Clients are able to perform preliminary research using both blood samples and various other biospecimens from the disease model mice that SMC offer.
* AND logical operation in case of multiple words.
Model cases
ServicesUPDATE
Fibrosis markers in the STAM™ model
2020.03.29
Currently, the most reliable method for NASH diagnosis is histological evaluation through liver biopsy. However, various drawbacks of the liver biopsy method, such as sampling error and burden to patients, have spurred the research and development of non-invasive early-diagnosis markers.
UPDATE
Advantage of Preclinical studies using STAM™
2020.03.13
We would like to introduce the advantages of preclinical research using our NASH-HCC model (STAMTM model).
NEWS RELEASE
Kanazawa Medical University’s publication on Diabetology & Metabolic Syndrome
2020.03.06
SMC announces that Kanazawa Medical University has published the results of a study using STAM™ model in Diabetology & Metabolic Syndrome
